Validation Data Gallery
|Positive WB detected in||HEK-293 cells, PC-3 cells, SH-SY5Y cells, C6 cells, NIH/3T3 cells, mouse kidney tissue, rat tissue|
|Positive IP detected in||mouse brain tissue|
|Positive FC detected in||HeLa cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB|
|Sample-dependent, check data in validation data gallery|
18295-1-AP targets HRAS-Specific in WB, IP, IHC, IF, FC, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Full Name||v-Ha-ras Harvey rat sarcoma viral oncogene homolog|
|Calculated molecular weight||21 kDa|
|Observed molecular weight||21 kDa|
|GenBank accession number||BC006499|
|Gene ID (NCBI)||3265|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
HRAS, also named as c-bas/has and RASH1, is v-Ha-ras Harvey rat sarcoma viral oncogene homolog from the mammalian ras gene family and it is a member of the small GTPase superfamily. RAS proteins are involved in signal transduction pathways, and bind GDP/GTP and possess intrinsic GTPase activity. Defects in HRAS are a cause of cancer. The antibody is specific to HRAS, can't recognize NRAS and KRAS.
|Product Specific Protocols|
|WB protocol for HRAS-Specific antibody 18295-1-AP||Download protocol|
|IHC protocol for HRAS-Specific antibody 18295-1-AP||Download protocol|
|IP protocol for HRAS-Specific antibody 18295-1-AP||Download protocol|
|FC protocol for HRAS-Specific antibody 18295-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Sci Transl Med
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Sci Transl Med
The ERBB network facilitates KRAS-driven lung tumorigenesis.
KARATE: PKA-induced KRAS4B-RHOA-mTORC2 supercomplex phosphorylates AKT in insulin signaling and glucose homeostasis
KRAS regulation by small non-coding RNAs and SNARE proteins.
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.
Clin Cancer Res
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
Benjamin (Verified Customer) (01-10-2020)
Identified HRAS around 20kDa mark on western blot.